$GASS

STEALTHGAS INC. Reports First Quarter 2026 Financial And Operating Results

StealthGas Inc. (NASDAQ: GASS) reported unaudited Q1 2026 results for the quarter ended March 31, 2026. Net income rose to $15.9m (basic EPS $0.43) from $12.8m in the prior quarter and $14.1m in Q1 2025. Revenue was $42.8m (+2% y/y). Results included $2.5m gain from a vessel sale and higher drydock costs from three drydockings. Cash was $131.2m; about 55% of 2026 fleet days are on period charters, with ~$100m contracted revenues (ex-JV).

Original reporting
Published Jun 5, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 2:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
STEALTHGAS INC. Reports First Quarter 2026 Financial And Operating Results — source image
Decision brief

The 30-second read

$GASSBullishMed
01

Why it matters

The print combines (1) profitability growth (net income and basic EPS), (2) operational updates (multiple charter extensions/new charters), and (3) balance-sheet support (cash increase, debt fully repaid, vessel sale proceeds expected). Together these improve near-term earnings visibility and liquidity, but also flag cost headwinds from drydocking and Middle East-related war-risk premiums.

02

Market read

Traders can update expectations for GASS’s 2026 contracted revenue coverage and near-term cash generation following the Q1 results and vessel sale/charter announcements.

03

What to watch

Adjusted EPS declined vs prior year (15.0m adjusted net income vs 16.1m) and joint-venture equity earnings fell, which may temper how much of the headline strength is recurring.

Relevance 9/10Novelty 8/10Timing: today’s pre-/post-market read-through to Q1 print and 2026 contracted revenue coverage

Background

StealthGas is an LPG ship-owning operator; the company’s earnings are sensitive to charter rates, drydock schedules, and war-risk insurance costs.

Company-level read

Ticker impact

$GASSBullishHigh confidence
Context

StealthGas reported Q1 2026 results with higher net income/EPS, plus new/extended LPG time charters and vessel sale proceeds boosting liquidity.

Expected impact

Likely near-term positive bias as traders price in improved earnings power and liquidity, partially offset by higher drydock and geopolitical war-risk costs.

Evidence & confidence

The release provides concrete Q1 financial datapoints (net income/EPS, revenue), operational drivers (drydock timing, war-risk insurance), and forward-looking contracted revenue/period coverage plus cash balance and debt repayment.

Market effects

War-risk insurance and LPG rate volatility tied to Middle East conflict are highlighted as key cost/earnings swing factors for LPG ship operators.

Geopolitical instability in the Middle East is explicitly linked to higher voyage costs, relevant to routes serving that demand corridor.

Contracted revenue coverage (~$100m total; ~54% of 2026 fleet days on period) can influence broader sentiment toward LPG shipping earnings durability.

Counterpoint

Higher drydock expenditures (three vessels vs one) and elevated war-risk insurance could pressure subsequent quarters despite the Q1 profitability improvement.

Key entities

  • STEALTHGAS INC.

    Reported unaudited Q1 2026 financial/operating results, charter coverage, and liquidity changes; subject of the article.

Related articles

$DEMedAI 8/10

Deere Earnings: Has the Stock Outrun the Farm Cycle?

Deere reported mixed earnings, with construction and forestry sales up 18% to $3.62B and ag equipment sales expected to decline 15-20%. Management raised full-year net income guidance to $4.75B-$5B. DE stock is up 35% in 2026, trading at a 35x P/E ratio.

$INTUHighAI 8/10

After-Hours Movers: INTU, SMTC, SYRE, ZM, NCNO

Intuit (INTU) fell 9% after lowering FY2027 guidance, missing EPS and revenue estimates. Semtech (SMTC) rose 3% on strong Q2 results and raised Q3 outlook. Spyre Therapeutics (SYRE) dropped 16% due to failed clinical trial results. Zoom (ZM) declined 3.5% despite Q2 beat, citing growth normalization. nCino (NCNO) fell 10% on near-term guidance concerns.